Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

被引:347
作者
Gordon, AN
Tonda, M
Sun, S
Rackoff, W
机构
[1] Arizona Gynecol Oncol, Phoenix, AZ 85006 USA
[2] Alza Corp, Mountain View, CA 94043 USA
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA
关键词
pegylated liposomal doxorubicin; topotecan; ovarian cancer; survival;
D O I
10.1016/j.ygyno.2004.07.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective. Provide long-term follow-up data for women treated in a randomized multicenter study of pegylated liposomal doxorubicin compared with topotecan. Methods. Patients with epithelial ovarian cancer that recurred after or failed to respond to first-line platinum-based chemotherapy were randomized to receive pegylated liposomal doxorubicin 50 mg/m(2) every 28 days (n=239) or topotecan 1.5 mg/m(2) per day for 5 days every 21 days (n=235). Patients were stratified prospectively based on response to initial platinum-based chemotherapy as well as the presence or absence of bulky disease. Most patients had been previously treated with platinum and taxanes (74% in the pegylated liposomal doxorubicin group and 72% in the topotecan group). Survival data are mature: 87% of patients have died (n=413). Results. There was an 18% reduction in the risk of death for patients treated with pegylated liposomal doxorubicin (median survival 62.7 weeks for pegylated liposomal doxorubicin and 59.7 weeks for topotecan-treated patients; HR=1.216; 95% confidence interval (CI) 1.000-1.478; P=0.050). The hazard ratio for all randomized subjects (includes those randomized, but never treated; n=481) was 1.23 (median survival 63.6 weeks for pegylated liposomal doxorubicin and 57.0 weeks for topotecan-treated patients; 95% CI 1.01-1.50; P=0.038). For patients with platinum-sensitive disease, there was a 30% reduction in the risk of death for the pegylated liposomal doxorubicin-treated group (median survival 107.9 weeks for pegylated liposomal doxorubicin and 70.1 weeks for topotecan-treated patients; HR=1.432; 95% CI 1.066-1.923; P=0.017). In patients with platinum-refractory disease, survival was similar between treatment groups. Conclusion. Long-term follow-up demonstrates that treatment with pegylated liposomal doxorubicin significantly prolongs survival compared with topotecan in patients with recurrent and refractory epithelial ovarian cancer. The survival benefit is pronounced in patients with platinum-sensitive disease. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 16 条
[1]
[Anonymous], CANC PRINCIPLES PRAC
[2]
[Anonymous], 1975, SEER CANC STAT REV
[3]
GABIZON A, 1994, CANCER RES, V54, P987
[4]
Polyethylene glycol coated (pegylated) liposomal doxorubicin - Rationale for use in solid tumours [J].
Gabizon, A ;
Martin, F .
DRUGS, 1997, 54 (Suppl 4) :15-21
[5]
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].
Gordon, AN ;
Fleagle, JT ;
Guthrie, D ;
Parkin, DE ;
Gore, ME ;
Lacave, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322
[6]
TREATMENT OF RELAPSED CARCINOMA OF THE OVARY WITH CISPLATIN OR CARBOPLATIN FOLLOWING INITIAL TREATMENT WITH THESE COMPOUNDS [J].
GORE, ME ;
FRYATT, I ;
WILTSHAW, E ;
DAWSON, T .
GYNECOLOGIC ONCOLOGY, 1990, 36 (02) :207-211
[7]
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma [J].
Huinink, WT ;
Lane, SR ;
Ross, GA .
ANNALS OF ONCOLOGY, 2004, 15 (01) :100-103
[8]
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J].
Huinink, WTB ;
Gore, M ;
Carmichael, J ;
Gordon, A ;
Malfetano, J ;
Hudson, I ;
Broom, C ;
Scarabelli, C ;
Davidson, N ;
Spanczynski, M ;
Bolis, G ;
Malmstrom, H ;
Coleman, R ;
Fields, SC ;
Heron, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2183-2193
[9]
Chemotherapy for recurrent ovarian cancer [J].
Kaye, SB .
LANCET, 2003, 361 (9375) :2094-2095
[10]
2ND-LINE PLATINUM THERAPY IN PATIENTS WITH OVARIAN-CANCER PREVIOUSLY TREATED WITH CISPLATIN [J].
MARKMAN, M ;
ROTHMAN, R ;
HAKES, T ;
REICHMAN, B ;
HOSKINS, W ;
RUBIN, S ;
JONES, W ;
ALMADRONES, L ;
LEWIS, JL .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :389-393